About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

NCT00386685·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Sanofi

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Metastatic breast cancer (MBC)
HER2 (Human Epidermal Growth Factor Receptor 2) positive: FISH (Fluorescent In Situ Hybridization) positive or IHC (Immunohistochemistry) 3+
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)
Adequate organs functions

You may not be if

More than one previous chemotherapy regimen for metastatic disease
Cardiac dysfunction

The record

StatusCompleted

PhasePhase 2

Taking part51

StartedJul 2006

UpdatedApr 12, 2011

Conditions

Breast Neoplasms

Where4

Sanofi-Aventis Administrative Office
Diegem, Belgium
Sanofi-Aventis Administrative Office
Paris, France
Sanofi-Aventis Administrative Office
Bromma, Sweden

Clareo Health | XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer